WuXi PharmaTech Co., Ltd. and Open Monoclonal Technology Expand Human Antibody Development and Commercial Opportunities for Asian Regional and Global Pharmaceutical Companies

SHANGHAI & PALO ALTO, Calif.--(BUSINESS WIRE)--WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the United States, and Open Monoclonal Technology, Inc. (OMT), an innovator in novel transgenic animals for development of human therapeutic antibodies, today announced a second agreement to expand WuXi’s use of OMT’s OmniRat™ and OmniMouse™ technologies to strengthen the development and commercial opportunities for WuXi’s Asian regional and global clients.